MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”)…
– Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia – –…
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era…
Pending the European Commission final decision, regimen offers a new standard of care for eligible MCL patients1,2Positive opinion reinforces Phase…
If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing…
Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected…
If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine…
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone”…
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared…
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal…